AUTHORS
Sahar Khan, MB BCh BAO, Harjot Singh Vohra2, Salman Basrai3, Esther Masih-Khan, PhD4, Steven Shih, MBChB, FRACP, FRCPA5, Donna Reece, M.D.6, Aaron Schimmer, MD PhD7, Suzanne Trudel, MD8, Keith Stewart, MD9, Sita Bhella, MD10, Vishal Kukreti, MD11, Chloe Yang, MD12, Guido Lancman, MD, MSc13, Rodger Tiedemann, MD, PhD14, Anca Prica, MD15, Sagi Abelson, PhD16, Christine Chen, MHPE, MD, FRCPC17
AFFILIATIONS
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada, Schulich School of Medicine & Dentistry, London, Ontario, Canada
2 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3 Ontario Institute for Cancer Research, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Ontario Institute for Cancer Research, Toronto, Ontario, Canada, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
14 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
15 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
16 Ontario Institute for Cancer Research, Toronto, Ontario, Canada
17 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
ABSTRACT
Introduction:
Presence of clonal hematopoietic mutations (CHIP) in Transplant Eligible Multiple Myeloma (TEMM) is well described and may have prognostic and therapeutic relevance (Chitre 2018; Mouhieddine 2020). Although CHIP mutations appear to portend advanced disease (Gelli 2024) and greater co-morbidity (Jaiswal 2017), post-transplant maintenance with immunomodulatory agents (IMiDs) may enhance anti-myeloma effect in CHIP mutated patients (pts)(Mouhieddine 2020; Wudhikarn 2021). Here we expand on our previous reports of a longitudinal trial studying mutation evolution from pre-transplant to 2 years post-transplant, in pts largely treated with non-IMID based induction (Khan 2024). Our previous results showed consistent rates of mutation prevalence over time, but notable variation in individual mutation dynamics.
Methods:
198 TEMM pts were enrolled, with planned samples for CHIP mutation testing at 4 time-points: pre-transplant (S1), 3 months post-transplant (S2), 1 year post-transplant (S3) and 2 years post-transplant (S4). Samples were sequenced using error-corrected SSCS targeted panel (Medeiros 2022); standard CHIP driver-gene variant calls used VAF ≥1%; though baseline calls (<1% VAF) were retained when confirmed at a later timepoint.
Results:
A total of 198 pts had S1 samples:
50% were ≥65 years at diagnosis, 117/198 (59%) male, 148/198 (75%) received CyBORD induction, 47/198 (24%) RVD or other IMID-based induction, 32/198 (16%) had tandem transplant. Of pts with available prognostic data, 64/116 (55%) had high risk cytogenetics (t(4;14), t(14;16), del(17), Amp1q), 48/170 (28%) ISS stage 3, 16/105 (15%) R-ISS stage 3. Lenalidomide maintenance was used in 154/177 transplanted pts (87%).
69/198 (35%) of pts were CHIP positive (+) in baseline samples, enriched for high-risk cytogenetics (71% vs 48%, p=0.026), with trends for age ≥65 (59% vs 45%, p 0.07) and higher R-ISS (25% vs 11% p=0.081). Documented cardiovascular disease was higher in CHIP+ (38% vs 22%, p=0.02). Other baseline/treatment characteristics including gender, B2M, Hb, platelets and ISS were not significantly different.
A minimum of 1 follow-up sample was available for 145/198 patients (73%), with 124/198 (63%) sequenced at S2, 86/198 (43%) at S3 and 43/198 (22%) at S4.
Mutation prevalences remained largely consistent across time-points, with ≥1 mutation identified at S1 in 35% (69/198 pts, 92 mutations), 35% at S2 (44/124 pts, 67 mutations), 50% at S3 (43/86 pts, 67 mutations) and 35% at S4 (15/43 pt, 22 mutations).
Mutation prevalence did not differ between pts receiving IMID versus non-IMID-based induction at any time-point.
DNMT3a and TET2 showed highest prevalence across all time-points (DNMT3A 48%, 48%, 49% and 60% and TET2 for 19%, 30%, 26% and 27% of CHIP+ pts at each of S1 to S4 respectively). In contrast, TP53 increased in prevalence: 9%, 14%, 14% and 20%.
Baseline mutations were tracked for 67 mutations (in 49 pts) with ≥1 sample for follow-up (latest sample used for reporting). Of these, 54% (36/67) cleared or reduced VAF by ≥50%, 18% (12/67) expanded VAF by ≥50% and remainder 28% (19/67) remained stable. Of individual genes, highest rates of clearance were seen at later timepoints (40% at S2 vs 58% at S3/S4), with most frequently cleared genes PPM1D (6/6, 100%) and ASXL1 (4/5, 80%).
Trends of emergent mutations were assessed in a subset of 145 pts with 2 or more sampling points. 41/145 patients (28%) acquired ≥1 emergent mutations. A similar proportion of DNMT3a and TET 2 mutations accounted for emergent as baseline mutation, whereas TP53 mutations increased from 7% of baseline to 16% of emergent mutations.
Conclusion:
The baseline prevalence of CHIP mutations is 35% in TEMM pts. CHIP+ pts were enriched for high risk cytogenetics and CV co-morbidity, with trends towards older age and higher R-ISS stage. Mutation prevalence was stable across pre- and post-transplant timepoints, but individual clonal trajectories varied. Most baseline clones contracted over time, with clearance rates peaking at 58% at later follow-up. Emergent mutations were common (28%), with patterns of mutations similar to baseline prevalence, with the exception of TP53 (new mutations increased from 7 to 16). Overall, our results show consistent trends of mutation prevalence within the cohort, but with considerable variation in mutation profiles over time in individual pts.
DISCLOSURES
Sahar Khan, MB BCh BAO: No relevant conflicts of interest to declare.